{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:50:18Z","timestamp":1777614618480,"version":"3.51.4"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Funds","award":["POCI\/01\/0145\/FEDER\/007728"],"award-info":[{"award-number":["POCI\/01\/0145\/FEDER\/007728"]}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","translationalres.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Research"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.trsl.2016.07.018","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T17:33:57Z","timestamp":1470245637000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems"],"prefix":"10.1016","volume":"180","author":[{"given":"Daniela","family":"Rodrigues","sequence":"first","affiliation":[]},{"given":"M\u00e1rcia","family":"Monteiro","sequence":"additional","affiliation":[]},{"given":"Carmen","family":"Jer\u00f3nimo","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Henrique","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Belo","sequence":"additional","affiliation":[]},{"given":"Maria de Lourdes","family":"Bastos","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Guedes de Pinho","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9884-4751","authenticated-orcid":false,"given":"M\u00e1rcia","family":"Carvalho","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.trsl.2016.07.018_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.urolonc.2009.04.015","article-title":"A survey of therapy for advanced renal cell carcinoma","volume":"28","author":"Basso","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.trsl.2016.07.018_bib2","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.2174\/092986712801661103","article-title":"Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis","volume":"19","author":"Urquidi","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.trsl.2016.07.018_bib3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3233\/CBM-2011-0176","article-title":"Renal cell carcinoma","volume":"9","author":"Cairns","year":"2010","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.trsl.2016.07.018_bib4","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.eururo.2007.03.035","article-title":"Renal cell carcinoma guideline","volume":"51","author":"Ljungberg","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.trsl.2016.07.018_bib5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1464-410x.2000.00708.x","article-title":"Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention","volume":"86","author":"Dhote","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.trsl.2016.07.018_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.7150\/jca.3718","article-title":"Diabetes and risk of renal cell carcinoma","volume":"3","author":"Habib","year":"2012","journal-title":"J Cancer"},{"key":"10.1016\/j.trsl.2016.07.018_bib7","series-title":"WHO Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs","author":"Eble","year":"2004"},{"key":"10.1016\/j.trsl.2016.07.018_bib8","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMra043172","article-title":"Renal-cell carcinoma","volume":"353","author":"Cohen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trsl.2016.07.018_bib9","first-page":"1","article-title":"Current management of advanced and metastatic renal cell carcinoma","volume":"7","author":"Ather","year":"2010","journal-title":"Urol J"},{"key":"10.1016\/j.trsl.2016.07.018_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.trsl.2016.07.018_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00345-004-0466-0","article-title":"Novel approaches in the therapy of metastatic renal cell carcinoma","volume":"23","author":"Lam","year":"2005","journal-title":"World J Urol"},{"key":"10.1016\/j.trsl.2016.07.018_bib12","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.4155\/bio.15.167","article-title":"NMR metabolomics of renal cancer: an overview","volume":"7","author":"Gil","year":"2015","journal-title":"Bioanalysis"},{"key":"10.1016\/j.trsl.2016.07.018_bib13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1586\/14737159.2016.1148601","article-title":"A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review","volume":"16","author":"Diekstra","year":"2016","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.trsl.2016.07.018_bib14","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3892\/ol.2012.1001","article-title":"Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinoma","volume":"5","author":"Takacova","year":"2013","journal-title":"Oncol Lett"},{"key":"10.1016\/j.trsl.2016.07.018_bib15","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/PAT.0000000000000145","article-title":"Tumour necrosis factor receptor-associated factor-1 (TRAF-1) expression is increased in renal cell carcinoma patient serum but decreased in cancer tissue compared with normal: potential biomarker significance","volume":"46","author":"Rajandram","year":"2014","journal-title":"Pathology"},{"key":"10.1016\/j.trsl.2016.07.018_bib16","first-page":"1801","article-title":"Serum amyloid A: a biomarker for renal cancer","volume":"32","author":"Fischer","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.trsl.2016.07.018_bib17","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000330851","article-title":"Sensitivity and specificity of urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 for the diagnosis of renal cell carcinoma","volume":"34","author":"Morrissey","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.trsl.2016.07.018_bib18","doi-asserted-by":"crossref","first-page":"256.e9","DOI":"10.1016\/j.urology.2013.09.026","article-title":"Urinary concentrations of aquaporin-1 and perilipin-2 in patients with renal cell carcinoma correlate with tumor size and stage but not grade","volume":"83","author":"Morrissey","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.trsl.2016.07.018_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.mayocp.2014.10.005","article-title":"Urine aquaporin 1 and perilipin 2 differentiate renal carcinomas from other imaged renal masses and bladder and prostate cancer","volume":"90","author":"Morrissey","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.trsl.2016.07.018_bib20","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2010.06.032","article-title":"EAU guidelines on renal cell carcinoma: the 2010 update","volume":"58","author":"Ljungberg","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.trsl.2016.07.018_bib21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.trsl.2016.07.018_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrneph.2011.152","article-title":"Metabolomics in the study of kidney diseases","volume":"8","author":"Weiss","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.trsl.2016.07.018_bib23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.14573\/altex.2013.2.209","article-title":"Metabolomics in toxicology and preclinical research","volume":"30","author":"Ramirez","year":"2013","journal-title":"ALTEX"},{"key":"10.1016\/j.trsl.2016.07.018_bib24","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s11306-014-0659-5","article-title":"Biomarkers in renal cell carcinoma: a metabolomics approach","volume":"10","author":"Monteiro","year":"2014","journal-title":"Metabolomics"},{"key":"10.1016\/j.trsl.2016.07.018_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.aca.2008.06.051","article-title":"Metabonomic profiling of renal cell carcinoma: high-resolution proton nuclear magnetic resonance spectroscopy of human serum with multivariate data analysis","volume":"624","author":"Gao","year":"2008","journal-title":"Anal Chim Acta"},{"key":"10.1016\/j.trsl.2016.07.018_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1582-4934.2009.00939.x","article-title":"Metabolic profiling reveals key metabolic features of renal cell carcinoma","volume":"15","author":"Catchpole","year":"2011","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.trsl.2016.07.018_bib27","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1158\/0008-5472.CAN-14-1703","article-title":"Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis","volume":"75","author":"Wettersten","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2016.07.018_bib28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2015.12.004","article-title":"An integrated metabolic atlas of clear cell renal cell carcinoma","volume":"29","author":"Hakimi","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trsl.2016.07.018_bib29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.trsl.2016.07.018_bib30","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1476-4598-5-64","article-title":"Pathway analysis of kidney cancer using proteomics and metabolic profiling","volume":"5","author":"Perroud","year":"2006","journal-title":"Mol Cancer"},{"key":"10.1016\/j.trsl.2016.07.018_bib31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/omi.2010.0094","article-title":"Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer","volume":"15","author":"Kim","year":"2011","journal-title":"OMICS"},{"key":"10.1016\/j.trsl.2016.07.018_bib32","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/ijc.29947","article-title":"H NMR metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism","volume":"138","author":"Cuperlovic-Culf","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.trsl.2016.07.018_bib33","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00432-011-1134-6","article-title":"Application of ex\u00a0vivo (1)H NMR metabonomics to the characterization and possible detection of renal cell carcinoma metastases","volume":"138","author":"Gao","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.trsl.2016.07.018_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/diseases4010007","article-title":"Renal Cell Carcinoma: A study through NMR-based metabolomics combined with transcriptomics","volume":"4","author":"Ragone","year":"2016","journal-title":"Diseases"},{"key":"10.1016\/j.trsl.2016.07.018_bib35","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/elps.201300228","article-title":"Distinct metabolic differences between various human cancer and primary cells","volume":"34","author":"Dettmer","year":"2013","journal-title":"Electrophoresis"},{"key":"10.1016\/j.trsl.2016.07.018_bib36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/(SICI)1099-1492(200004)13:2<64::AID-NBM612>3.0.CO;2-X","article-title":"Distinction between normal and renal cell carcinoma kidney cortical biopsy samples using pattern recognition of (1)H magic angle spinning (MAS) NMR spectra","volume":"13","author":"Tate","year":"2000","journal-title":"NMR Biomed"},{"key":"10.1016\/j.trsl.2016.07.018_bib37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0731-7085(97)00176-3","article-title":"Biochemical classification of kidney carcinoma biopsy samples using magic-angle-spinning 1H nuclear magnetic resonance spectroscopy","volume":"17","author":"Moka","year":"1998","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.trsl.2016.07.018_bib38","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1021\/pr100226m","article-title":"(1)H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool","volume":"9","author":"Zira","year":"2010","journal-title":"J Proteome Res"},{"key":"10.1016\/j.trsl.2016.07.018_bib39","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1021\/pr101161u","article-title":"LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery","volume":"10","author":"Lin","year":"2011","journal-title":"J Proteome Res"},{"key":"10.1016\/j.trsl.2016.07.018_bib40","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1002\/ijc.26274","article-title":"Urinary acylcarnitines are altered in human kidney cancer","volume":"130","author":"Ganti","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.trsl.2016.07.018_bib41","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s10334-005-0107-7","article-title":"Investigation of multidrug resistance in cultured human renal cell carcinoma cells by 31P-NMR spectroscopy and treatment survival assays","volume":"18","author":"Lutz","year":"2005","journal-title":"MAGMA"},{"key":"10.1016\/j.trsl.2016.07.018_bib42","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/nbm.758","article-title":"31P NMR spectroscopy of blood plasma: determination and quantification of phospholipid classes in patients with renal cell carcinoma","volume":"15","author":"Sullentrop","year":"2002","journal-title":"NMR Biomed"},{"key":"10.1016\/j.trsl.2016.07.018_bib43","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1039\/c0an00265h","article-title":"Direct infusion mass spectrometry or liquid chromatography mass spectrometry for human metabonomics? A serum metabonomic study of kidney cancer","volume":"135","author":"Lin","year":"2010","journal-title":"Analyst"},{"key":"10.1016\/j.trsl.2016.07.018_bib44","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/pmic.201200016","article-title":"LC-MS-based serum metabolic profiling for genitourinary cancer classification and cancer type-specific biomarker discovery","volume":"12","author":"Lin","year":"2012","journal-title":"Proteomics"},{"key":"10.1016\/j.trsl.2016.07.018_bib45","doi-asserted-by":"crossref","first-page":"94","DOI":"10.59566\/IJBS.2012.8094","article-title":"In\u00a0vitro and in\u00a0vivo (1)H-MR spectroscopic examination of the renal cell carcinoma","volume":"8","author":"Sullentrop","year":"2012","journal-title":"Int J Biomed Sci"},{"key":"10.1016\/j.trsl.2016.07.018_bib46","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1158\/2159-8290.CD-13-0696","article-title":"L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer","volume":"4","author":"Shim","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.trsl.2016.07.018_bib47","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1021\/pr070063h","article-title":"Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis","volume":"6","author":"Yang","year":"2007","journal-title":"J Proteome Res"},{"key":"10.1016\/j.trsl.2016.07.018_bib48","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1021\/pr4004135","article-title":"HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease","volume":"12","author":"Tripathi","year":"2013","journal-title":"J Proteome Res"},{"key":"10.1016\/j.trsl.2016.07.018_bib49","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.radonc.2009.06.025","article-title":"Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells","volume":"92","author":"Feron","year":"2009","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.trsl.2016.07.018_bib50","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.yexmp.2010.08.006","article-title":"Cancer metabolism: the Warburg effect today","volume":"89","author":"Ferreira","year":"2010","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.trsl.2016.07.018_bib51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-065X.2012.01155.x","article-title":"Metabolic reprogramming and metabolic dependency in T cells","volume":"249","author":"Wang","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1016\/j.trsl.2016.07.018_bib52","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1021\/pr070172w","article-title":"Evaluation of tubulointerstitial lesions' severity in patients with glomerulonephritides: an NMR-based metabonomic study","volume":"6","author":"Psihogios","year":"2007","journal-title":"J Proteome Res"},{"key":"10.1016\/j.trsl.2016.07.018_bib53","doi-asserted-by":"crossref","first-page":"F551","DOI":"10.1152\/ajprenal.00218.2014","article-title":"ADAM17 promotes proliferation of collecting duct kidney epithelial cells through ERK activation and increased glycolysis in polycystic kidney disease","volume":"307","author":"Beck Gooz","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.trsl.2016.07.018_bib54","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1476-4598-7-72","article-title":"Metabolite profiling of human colon carcinoma\u2013deregulation of TCA cycle and amino acid turnover","volume":"7","author":"Denkert","year":"2008","journal-title":"Mol Cancer"},{"key":"10.1016\/j.trsl.2016.07.018_bib55","first-page":"11052","article-title":"Metabolomics in bladder cancer: a systematic review","volume":"8","author":"Cheng","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.trsl.2016.07.018_bib56","doi-asserted-by":"crossref","first-page":"19611","DOI":"10.1073\/pnas.1117773108","article-title":"Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of \u03b1-ketoglutarate to citrate to support cell growth and viability","volume":"108","author":"Wise","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trsl.2016.07.018_bib57","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature10602","article-title":"Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia","volume":"481","author":"Metallo","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.trsl.2016.07.018_bib58","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1021\/pr4000448","article-title":"Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry","volume":"12","author":"Pasikanti","year":"2013","journal-title":"J Proteome Res"},{"key":"10.1016\/j.trsl.2016.07.018_bib59","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3233\/CBM-2009-0115","article-title":"Taurine - a possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by 1H NMR spectroscopy","volume":"6","author":"Srivastava","year":"2010","journal-title":"Cancer Biomark"},{"key":"10.1016\/j.trsl.2016.07.018_bib60","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1007\/s11033-012-1764-z","article-title":"Revealing the metabonomic variation of EC using (1)H-NMR spectroscopy and its association with the clinicopathological characteristics","volume":"39","author":"Hasim","year":"2012","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.trsl.2016.07.018_bib61","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1021\/pr901081y","article-title":"Urinary metabonomic study on colorectal cancer","volume":"9","author":"Qiu","year":"2010","journal-title":"J Proteome Res"},{"key":"10.1016\/j.trsl.2016.07.018_bib62","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0083","article-title":"Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities","volume":"3","author":"Cairns","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.trsl.2016.07.018_bib63","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ccr.2010.08.009","article-title":"Targeting mitochondrial glutaminase activity inhibits oncogenic transformation","volume":"18","author":"Wang","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trsl.2016.07.018_bib64","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.seminoncol.2014.02.005","article-title":"Tumor macroenvironment and metabolism","volume":"41","author":"Al-Zoughbi","year":"2014","journal-title":"Semin Oncol"},{"key":"10.1016\/j.trsl.2016.07.018_bib65","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1753-4887.2009.00246.x","article-title":"Choline: an essential nutrient for public health","volume":"67","author":"Zeisel","year":"2009","journal-title":"Nutr Rev"},{"key":"10.1016\/j.trsl.2016.07.018_bib66","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0968-0004(99)01365-1","article-title":"Interactions among pathways for phosphatidylcholine metabolism, CTP synthesis and secretion through the Golgi apparatus","volume":"24","author":"Kent","year":"1999","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.trsl.2016.07.018_bib67","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M111.007922","article-title":"Bladder cancer determination via two urinary metabolites: a biomarker pattern approach","volume":"10","author":"Huang","year":"2011","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.trsl.2016.07.018_bib68","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2116\/analsci.28.451","article-title":"NMR-based metabolomic analysis of human bladder cancer","volume":"28","author":"Cao","year":"2012","journal-title":"Anal Sci"},{"key":"10.1016\/j.trsl.2016.07.018_bib69","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/hed.10125","article-title":"An ex\u00a0vivo study exploring the diagnostic potential of 1H magnetic resonance spectroscopy in squamous cell carcinoma of the head and neck region","volume":"24","author":"El-Sayed","year":"2002","journal-title":"Head Neck"},{"key":"10.1016\/j.trsl.2016.07.018_bib70","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1593\/neo.81396","article-title":"Early stage diagnosis of oral cancer using 1H NMR-based metabolomics","volume":"11","author":"Tiziani","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.trsl.2016.07.018_bib71","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4137\/BMI.S6794","article-title":"H HRMAS NMR derived bio-markers related to tumor grade, tumor cell fraction, and cell proliferation in prostate tissue samples","volume":"6","author":"Stenman","year":"2011","journal-title":"Biomark Insights"},{"key":"10.1016\/j.trsl.2016.07.018_bib72","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1158\/0008-5472.CAN-04-4106","article-title":"Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy","volume":"65","author":"Cheng","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2016.07.018_bib73","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/nbm.992","article-title":"Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters","volume":"19","author":"Sitter","year":"2006","journal-title":"NMR Biomed"},{"key":"10.1016\/j.trsl.2016.07.018_bib74","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1096\/fasebj.13.10.1169","article-title":"Regulation of hepatic glutathione synthesis: current concepts and controversies","volume":"13","author":"Lu","year":"1999","journal-title":"FASEB J"},{"key":"10.1016\/j.trsl.2016.07.018_bib75","first-page":"793","article-title":"Translational studies of glutathione in bladder cancer cell lines and human specimens","volume":"3","author":"Pendyala","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.trsl.2016.07.018_bib76","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1039\/C4MB00250D","article-title":"Structural mass spectrometry of tissue extracts to distinguish cancerous and non-cancerous breast diseases","volume":"10","author":"Hines","year":"2014","journal-title":"Mol Biosyst"},{"key":"10.1016\/j.trsl.2016.07.018_bib77","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/mrm.22303","article-title":"Quantitative two-dimensional HRMAS 1H-NMR spectroscopy-based metabolite profiling of human cancer cell lines and response to chemotherapy","volume":"63","author":"Bayet-Robert","year":"2010","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.trsl.2016.07.018_bib78","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1158\/0008-5472.CAN-13-0308","article-title":"Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2016.07.018_bib79","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/carcin\/bgu226","article-title":"NMR metabolomics of human lung tumours reveals distinct metabolic signatures for adenocarcinoma and squamous cell carcinoma","volume":"36","author":"Rocha","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.trsl.2016.07.018_bib80","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jnutbio.2004.02.006","article-title":"Cellular mechanisms of vitamin E uptake: relevance in alpha-tocopherol metabolism and potential implications for disease","volume":"15","author":"Mardones","year":"2004","journal-title":"J Nutr Biochem"},{"key":"10.1016\/j.trsl.2016.07.018_bib81","doi-asserted-by":"crossref","first-page":"10795","DOI":"10.1158\/0008-5472.CAN-06-0755","article-title":"Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors","volume":"66","author":"Denkert","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.trsl.2016.07.018_bib82","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?","volume":"8","author":"Trachootham","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.trsl.2016.07.018_bib83","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrclinonc.2014.202","article-title":"Pragmatic issues in biomarker evaluation for targeted therapies in cancer","volume":"12","author":"de Gramont","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.trsl.2016.07.018_bib84","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/092986713804806621","article-title":"Metabolomics analysis for biomarker discovery: advances and challenges","volume":"20","author":"Monteiro","year":"2013","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.trsl.2016.07.018_bib85","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mehy.2006.04.048","article-title":"Cancer cachexia demonstrates the energetic impact of gluconeogenesis in human metabolism","volume":"67","author":"Bongaerts","year":"2006","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.trsl.2016.07.018_bib86","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","article-title":"Mechanisms of cancer cachexia","volume":"89","author":"Tisdale","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1016\/j.trsl.2016.07.018_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpba.2013.08.041","article-title":"Metabolomics in cancer biomarker discovery: current trends and future perspectives","volume":"87","author":"Armitage","year":"2014","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.trsl.2016.07.018_bib88","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s11306-014-0746-7","article-title":"Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review","volume":"11","author":"Emwas","year":"2014","journal-title":"Metabolomics"},{"key":"10.1016\/j.trsl.2016.07.018_bib89","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11306-006-0037-z","article-title":"Statistical strategies for avoiding false discoveries in metabolomics and related experiments","volume":"2","author":"Broadhurst","year":"2006","journal-title":"Metabolomics"},{"key":"10.1016\/j.trsl.2016.07.018_bib90","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s11306-012-0482-9","article-title":"Translational biomarker discovery in clinical metabolomics: an introductory tutorial","volume":"9","author":"Xia","year":"2013","journal-title":"Metabolomics"},{"key":"10.1016\/j.trsl.2016.07.018_bib91","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00345-007-0199-y","article-title":"Key clinical issues in renal cancer: a challenge for proteomics","volume":"25","author":"Banks","year":"2007","journal-title":"World J Urol"},{"key":"10.1016\/j.trsl.2016.07.018_bib92","doi-asserted-by":"crossref","first-page":"e37395","DOI":"10.1371\/journal.pone.0037395","article-title":"A panel of serum MicroRNAs as specific biomarkers for diagnosis of compound- and herb-induced liver injury in rats","volume":"7","author":"Su","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.trsl.2016.07.018_bib93","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2008.04.041","article-title":"Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence","volume":"110","author":"Havrilesky","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.trsl.2016.07.018_bib94","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11306-013-0595-9","article-title":"Plasma metabolomics reveals a potential panel of biomarkers for early diagnosis in acute coronary syndrome","volume":"10","author":"Laborde","year":"2013","journal-title":"Metabolomics"},{"key":"10.1016\/j.trsl.2016.07.018_bib95","first-page":"1121","article-title":"Acute lung injury in patients with traumatic injuries: utility of a panel of biomarkers for diagnosis and pathogenesis","volume":"68","author":"Fremont","year":"2010","journal-title":"J Trauma"},{"key":"10.1016\/j.trsl.2016.07.018_bib96","first-page":"3195","article-title":"Ex\u00a0vivo HR-MAS magnetic resonance spectroscopy of normal and malignant human renal tissues","volume":"27","author":"Righi","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.trsl.2016.07.018_bib97","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1021\/pr500966h","article-title":"Metabonomic profiling of bladder cancer","volume":"14","author":"Chan","year":"2015","journal-title":"J Proteome Res"},{"key":"10.1016\/j.trsl.2016.07.018_bib98","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1158\/0008-5472.CAN-11-3105","article-title":"Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis","volume":"72","author":"Ganti","year":"2012","journal-title":"Cancer Res"}],"container-title":["Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524416301529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931524416301529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T17:36:19Z","timestamp":1718732179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524416301529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":98,"alternative-id":["S1931524416301529"],"URL":"https:\/\/doi.org\/10.1016\/j.trsl.2016.07.018","relation":{},"ISSN":["1931-5244"],"issn-type":[{"value":"1931-5244","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems","name":"articletitle","label":"Article Title"},{"value":"Translational Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trsl.2016.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}